SinoMab BioScience Ltd 03681
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- HKD 1.90
- Day Range
- HKD 1.89–1.90
- 52-Week Range
- HKD 1.03–1.95
- Bid/Ask
- HKD 1.85 / HKD 1.90
- Market Cap
- HKD 2.06 Bil
- Volume/Avg
- 213,300 / 205,317
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1,273.60
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
SinoMab BioScience Ltd is a biopharmaceutical company. The company is engaged in the research, development, manufacturing, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product, SM03 (Suciraslimab), is a potential global first-in target mAb for the treatment of rheumatoid arthritis (RA) and potentially for the treatment of other immunological diseases such as systemic lupus erythematosus (SLE), Sjogren’s syndrome (SS) as well as non-Hodgkin’s lymphoma (NHL), and other indications. The group derives revenue from Hong Kong.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 215
- Website
- https://www.sinomab.com
Comparables
Valuation
Metric
|
03681
|
KNSA
|
VRDN
|
---|---|---|---|
Price/Earnings (Normalized) | — | 182.45 | — |
Price/Book Value | 6.00 | 3.29 | 3.53 |
Price/Sales | 1,273.60 | 4.80 | 2,194.98 |
Price/Cash Flow | — | 121.87 | — |
Price/Earnings
03681
KNSA
VRDN
Financial Strength
Metric
|
03681
|
KNSA
|
VRDN
|
---|---|---|---|
Quick Ratio | 1.39 | 3.57 | 17.93 |
Current Ratio | 1.56 | 4.21 | 18.26 |
Interest Coverage | −36.86 | — | −137.76 |
Quick Ratio
03681
KNSA
VRDN
Profitability
Metric
|
03681
|
KNSA
|
VRDN
|
---|---|---|---|
Return on Assets (Normalized) | −24.30% | 8.64% | −42.76% |
Return on Equity (Normalized) | −57.97% | 10.14% | −82.42% |
Return on Invested Capital (Normalized) | −27.69% | 9.90% | −50.70% |
Return on Assets
03681
KNSA
VRDN
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Vnbqgzlsv | Jcjp | $545.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Fmcglwhtz | Pbxczz | $105.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Sjpmtfvm | Tqxqc | $103.7 Bil | |
MRNA
| Moderna Inc | Kgkshrcz | Dwczt | $47.9 Bil | |
ARGX
| argenx SE ADR | Zqhrtvr | Ycgd | $22.9 Bil | |
BNTX
| BioNTech SE ADR | Pxpgldqbh | Lvrjn | $22.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Qdskzrsnk | Dwjbwy | $19.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vhjwlypfm | Rqkqz | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Zfkywvmcgn | Fspcnx | $12.8 Bil | |
INCY
| Incyte Corp | Qswfjqzp | Yldsqc | $12.1 Bil |